Adaptive Biotechnologies (Adaptive Biotechnologies) Short Percentage of Float

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Adaptive Biotechnologies's Short Percentage of Float

For the Biotechnology subindustry, Adaptive Biotechnologies's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Short Percentage of Float falls into.

Adaptive Biotechnologies (Adaptive Biotechnologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Executives

Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Leslie Trigg	director	C/O OUTSET MEDICAL, 1830 BERING ROAD, SAN JOSE CA 95112
Kevin T Conroy	director	5505 ENDEAVOR LANE, MADISON WI 53719
Robert Hershberg	director	3005 FIRST AVENUE, SEATTLE WA 98121
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102